News | May 23, 2024
Asymchem acquires former Pfizer small molecule API pilot plant in Sandwich, UK
Establishing Asymchem’s first manufacturing footprint in Europe
Establishing Asymchem’s first manufacturing footprint in Europe
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Pfizer INDovation program partners with NIPER Ahmedabad to incubate healthcare startups
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
Subscribe To Our Newsletter & Stay Updated
